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Abstract
Background: Modeling of the transmission dynamics of typhoid allows for an evaluation of the potential direct and indirect
effects of vaccination; however, relevant typhoid models rooted in data have rarely been deployed.
Methodology/Principal Findings: We developed a parsimonious age-structured model describing the natural history and
immunity to typhoid infection. The model was fit to data on culture-confirmed cases of typhoid fever presenting to
Christian Medical College hospital in Vellore, India from 2000–2012. The model was then used to evaluate the potential
impact of school-based vaccination strategies using live oral, Vi-polysaccharide, and Vi-conjugate vaccines. The model was
able to reproduce the incidence and age distribution of typhoid cases in Vellore. The basic reproductive number (R0)o f
typhoid was estimated to be 2.8 in this setting. Vaccination was predicted to confer substantial indirect protection leading
to a decrease in the incidence of typhoid in the short term, but (intuitively) typhoid incidence was predicted to rebound 5–
15 years following a one-time campaign.
Conclusions/Significance: We found that model predictions for the overall and indirect effects of vaccination depend
strongly on the role of chronic carriers in transmission. Carrier transmissibility was tentatively estimated to be low,
consistent with recent studies, but was identified as a pivotal area for future research. It is unlikely that typhoid can be
eliminated from endemic settings through vaccination alone.
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Introduction
Typhoid has a long and storied history as a public health
scourge. Salmonella enterica serovar Typhi (S. Typhi) is a human-
restricted bacterial pathogen transmitted via faecal contamination
of food and water. While improvements in water and sanitation
led to the elimination of typhoid from most developed countries
during the twentieth century, the global burden of typhoid fever
has recently been estimated to be between 13.5 and 26.9 million
episodes and 190,000 to 216,000 deaths annually [1–3].
Children in South Asia carry one of the highest typhoid burdens
in the world [1,4]. The emergence of antimicrobial resistance has
further compounded the problem, with treatment failure and
complications becoming more common [5]. Several public health
authorities have suggested school-based vaccination programs as a
means of control [6]. Such programs have been successfully
carried out in Thailand, China, and Viet Nam [7,8].
There are two widely licensed vaccines against typhoid [9].
Ty21a is a multi-dose live oral vaccine, inducing both cellular and
antibody-mediated immune responses [10], while Vi polysaccha-
ride (ViPS) is a single-dose injectable vaccine that induces an
antibody response to the capsular Vi antigen [11]. Both vaccines
demonstrated moderate efficacy in field trials [12,13]. Notably,
neither is licensed for use in children ,2 years old. There are also
several Vi conjugate vaccines (ViCV) in advanced stages of
development. Existing data predicts that ViCV can be effectively
administered to infants and will elicit a stronger and longer-lasting
immune response than ViPS [14,15].
Cluster randomized trials suggest that typhoid vaccination may
induce some herd immunity, but results have been variable
PLOS Neglected Tropical Diseases | www.plosntds.org 1 January 2014 | Volume 8 | Issue 1 | e2642[16,17]. Mathematical models of typhoid transmission dynamics
rooted in data can help interpret the trial results and generalize the
findings to the long-term impact of vaccination at various coverage
levels, but few such models currently exist [18–21]. Mathematical
modeling is highly pertinent for deciding how ViCV can be best
utilized when they become widely available.
We developed a model for the transmission dynamics of typhoid
to quantify the expected population-level impact of vaccination. We
fit our model to a 12-year time series of culture-confirmed cases
from Vellore, Indiato estimate important unknown parameters. We
then examined the potential impact of vaccination under a variety
of assumptions about vaccine efficacy and duration of protection,
reflecting the characteristics of the currently available and next
generation vaccines. We also explored how chronic carriers
influenced the expected indirect and overall effects of vaccination.
Methods
Ethics statement
The study protocol was approved by the Oxford Tropical
Research Ethics Committee.
Data sources
Data on patients hospitalized with typhoid or paratyphoid
between January 1, 2000 and February 29, 2012 were obtained
fromChristianMedical College (CMC)inVellore,India.TheCMC
hospital is a 2,695-bed referral tertiary care facility in Tamil Nadu.
We obtained data on patient age, primary and secondary diagnoses,
discharge date, and whether they died. All patient identifiers were
removed. We limited our analysis to patients with culture-confirmed
typhoid (A01.0 according to the ICD10-CM), and aggregated the
data by week of discharge and patient age in 5-year age groups.
Approximately 45% of S. Typhi strains isolated between 1999 and
2002 were resistant to ampicillin, chloramphenicol, and co-
trimoxazole, although the percentage of resistant isolates was
decreasing over this time period (V. Balaji, unpublished data).
The catchment population for CMC hospital is not well
defined, but likely includes a subset of Vellore district, surrounding
populations, and patients referred from other states. We obtained
demographic data on the population of Vellore district and the
crude birth and death rates in Tamil Nadu from 1971 to 2015
(http://www.indiastat.com), and derived estimates of the weekly
number of births (Text S1). To simulate the potential impact of
vaccination, we assumed the birth and death rates remained at the
most recently observed levels.
Model description
Our model for the transmission dynamics of typhoid is
illustrated in Figure 1. The essential features include: (1) a
distinction between ‘‘primary infection’’ (I1) of fully susceptible
individuals (S1), which may lead to hospitalization, and subsequent
subclinical infection (i.e. short-term carriage) (I2) of partially
susceptible individuals (S2); (2) loss of immunity (R) to subclinical
typhoid infection and boosting of clinical immunity through
repeated subclinical infections; (3) the inclusion of a chronic carrier
state (C), in which a small fraction of infections lead to life-long
carriage of typhoid [22,23]; and (4) a balance between ‘‘short-
cycle’’ transmission via contamination of food, drinking water, etc.
in the immediate environment and ‘‘long-cycle’’ transmission via
contamination of the water supply (W), the latter of which we
assume varies seasonally. Both short- and long-term carriers
contribute to transmission, but not necessarily at the same rate as
primary infections.
Model parameters are described in Table 1; a full description of
the model can be found in the Text S1. We fixed the value of
parameters described in the literature then estimated the
remaining parameters by fitting the model to the Vellore data
(Table 1). The basic reproductive number (R0) can be calculated
from the model parameters and broken down into its components
in order to better understand the contribution of short-cycle (R0,p)
versus long-cycle (R0,w) transmission, and the relative role of
carriers compared to primary infections (Text S1).
Model fitting and validation
We fit our model to the Vellore data by maximizing the
likelihood assuming the weekly number of reported typhoid cases
in each age group is Poisson-distributed with a mean equal to a
fraction f of the model-predicted number of primary infections
(Text S1). The reporting fraction f incorporates the probability
that an individual with clinical typhoid infection in Vellore district
will seek care at (or be referred to) CMC hospital, be admitted as
an in-patient, and be culture-confirmed; hence, it takes into
account many factors, including the probability of primary
infection leading to clinical typhoid, treatment-seeking behavior,
and culture sensitivity (which is relatively poor).
We validated our best-fit model by comparing predictions for
the indirect and overall effectiveness of vaccination using ViPS to
observations from cluster randomized trials conducted in Kolkata,
India and Karachi, Pakistan [16,17]. The indirect effectiveness is
defined as the reduction in the incidence rate among unvaccinated
individuals in a partially vaccinated population compared to the
incidence rate in a completely unvaccinated population, while the
overall effectiveness is defined as the incidence rate among
vaccinated and unvaccinated individuals in a partially vaccinated
population compared to the incidence rate in a completely
unvaccinated population [24]. Preliminary analyses revealed that
the predicted level of indirect and overall protection was strongly
dependent on assumptions about the proportion of transmission
due to carriers (cp). We therefore examined model predictions for
vaccine effectiveness for cp from 5% to 95% by varying the relative
infectiousness of carriers (r).
Vaccination
We modeled vaccination in two ways to accommodate the
different immune mechanisms of the live oral versus Vi-based
vaccines (Figure S1, Text S1). We assumed the vaccine efficacy for
Ty21a was 48% in accordance with a recent meta-analysis;
waning of immunity to was assumed to mimic natural immunity
[9]. For ViPS, we assumed an initial vaccine efficacy of 80% and a
mean duration of protection of 3 years, while for ViCV, we
assumed an initial efficacy of 95.6% and a duration of 19.2 years,
based on a comparison between the predicted direct effect (i.e.
reduction in the cumulative incidence among vaccinated versus
Author Summary
We developed a mathematical model for the transmission
dynamics of typhoid in order to evaluate the potential
direct and indirect (i.e. herd immunity) effects of vaccina-
tion. The model was fit to data from Vellore, India and
validated against the results of cluster randomized vaccine
trials. We evaluated a variety of school-based vaccination
strategies and found that typhoid vaccination is expected
to lead to short-term indirect protection and a decrease in
typhoid incidence, but vaccination alone is unlikely to lead
to elimination. The level of indirect protection was found
to depend on assumptions about the role of chronic
carriers, identifying an important area for future research.
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PLOS Neglected Tropical Diseases | www.plosntds.org 2 January 2014 | Volume 8 | Issue 1 | e2642Figure 1. Model for the transmission dynamics of typhoid. (A) Diagram of model structure. Model parameters are defined in Table 1. (B)
Weekly incidence of observed (blue line) and model-predicted (thick red line) typhoid inpatients at Christian Medical College hospital in Vellore, India.
The thin red line represents a simulated incidence time-series for the best-fit model assuming the number of cases each week is Poisson distributed
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observed during trials (Figure S2) [9].
For all three vaccines, we examined the following school-based
vaccination strategies:
+ One-time campaign among school-aged children (6–15 years
old)
+ Routine vaccination at school entry (6 years old)
+ Routine vaccination at school entry plus a one-time catch-up
campaign among 6–15 year olds.
Since one of the goals of ViCV is to provide immunity from a
younger age, we explored the potential impact of routine
vaccination at 9 months old, with and without a catch-up campaign
among 9-month to 15-year olds. We also examined the benefit of
including revaccination with ViPS every three years (at 6, 9, and 12
years of age), and whether it would be possible to eliminate typhoid
using ViCV and an aggressive strategy consisting of one-time mass
vaccination followed by routine vaccination of infants (at 9 months
old) and school-aged children (at 6 and 12 years old).
We evaluated the impact of vaccination on the projected
typhoid incidence over time assuming a coverage level of 80%,
and compared this to the projected incidence without vaccination
and if the vaccine was assumed to provide direct protection only
(i.e. the population direct effect, which we define as the reduction in
incidence that would be predicted by a static model that did not
account for the transmission dynamics of infection; Text S1). We
also evaluated the overall vaccine effectiveness (i.e. fractional
reduction in cumulative typhoid incidence) over the first 10 years
following vaccine introduction for coverage levels of 0–100%.
Finally, the expected number of typhoid cases prevented per 1,000
vaccine courses administered was calculated over 1–20 years
following vaccine introduction at 80% coverage, assuming 10% of
primary infections result in clinical typhoid cases.
Comparison between the impact of vaccination and
improvements in sanitation
We also explored the potential impact of improvements in water
quality and sanitation, with and without vaccination, under a
variety of assumptions about the proportion of transmission due to
carriers (cp) and the proportion of transmission that is water-borne
(and therefore potentially reduced through such broad-scale
interventions). To model the impact of sanitation, R0,w was
reduced from its starting value (25% to 100% of R0=2.8) to 0
linearly over a 30-year period (years 5–35). The additional impact
of vaccination was assessed for the ViPS vaccine assuming routine
vaccination of 6 year olds plus a catch-up campaign among 6–15
year olds beginning in year 5 with 80% coverage.
All analyses were carried out using MATLAB version 7.14
(MathWorks, Natick, MA).
Results
Model fit to the observed incidence of typhoid in Vellore
The weekly incidence of culture-confirmed typhoid infections at
CMC hospital varied from 0 to 25 cases per week, while the
with a mean equal to the model-predicted incidence. (C) Age distribution of observed (blue) and model-predicted (red) typhoid cases.
doi:10.1371/journal.pntd.0002642.g001
Table 1. Fixed model parameters and parameters estimated from the best-fit model for typhoid inpatients at Christian Medical
College hospital in Vellore, India.
Fixed parameters
Parameter definition Symbol Value Source
Birth rate B 14.9–19.2 live births per 1,000 Census data
Natural mortality rate m 7.2–8.2 deaths per 1,000 Census data
Duration of infectiousness 1/d 4 weeks [36]
Fraction infected who become chronic carriers h 0.003–0.101 depending on age [33]
Disease-induced mortality a 0.001 Assumption, [1]
Duration of temporary full immunity to infection 1/v 104 weeks Assumption*, [30]
Rate of shedding into the water supply c 1 infectious unit/week Assumption
{
Rate of decay of infectious particles from water supply j 1/3 week
21 [37]
Estimated parameters
Parameter definition Symbol Estimate
Basic reproductive number for short-cycle transmission R0,p 2.49
Basic reproductive number for long-cycle transmission R0,w 0.28
Amplitude of seasonal forcing (long-cycle transmission) q 0.69
Seasonal offset parameter (timing of seasonal peak) w 18.2 weeks
Rate of waning immunity to clinical disease e 2.68610
211
Relative infectiousness of chronic and short-term carriers r 0.01
Reporting fraction f 0.0052
*The best-fit model was not sensitive to this parameter.
{Inseparable from the estimated long-cycle transmission parameter, bw.
doi:10.1371/journal.pntd.0002642.t001
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cases per week (Figure S3A). Thus, much of the burden of enteric
fever in this population is due to S. Typhi and therefore could
potentially be prevented by a Vi-based vaccine. Cases occurred
throughout the year; there was only weak seasonal variability in
incidence, which did not appear to be correlated with rainfall
(Figure S3B). The mean age of typhoid patients was 17.6 years,
with burden generally decreasing with age (Figure S3C).
Our best-fit model was able to reproduce the incidence pattern
and age distribution of typhoid cases in Vellore (Figure 1B,C).
Point estimates of key parameters were well located and
remarkably insensitive to the fixed parameter assumptions,
indicating that the model is not over-specified relative to the
age-structured time series data used for fitting (Figure S4, Table
S1). The basic reproductive number for the best-fit model was
R0=2.8 (95% CI: 2.6, 2.9). Short-cycle transmission accounted for
90% of the R0 value (Table 1), but estimates of R0,w and R0,p were
highly correlated (Figure S4). Following recovery from infection,
most individuals were estimated to remain immune to clinical
disease (e <0). The proportion of symptomatic typhoid infections
in Vellore district that seek care at CMC hospital, are admitted as
inpatients and microbiologically confirmed was estimated to be
low (f=0.0052). Assuming 10% of primary infections result in
clinical typhoid, the model-predicted an annual incidence rate of
146 cases per 100,000 person-years, which is consistent with the
estimated incidence rate in Kolkata, India [16]. The prevalence of
chronic carriers was predicted to increase with age (Figure S5),
and was estimated to be ,2% among 30–40 year olds, which is
similar to the prevalence of carriage among patients undergoing
cholecystectomy in Kathmandu, Nepal [25]. We also examined
the impact of vaccination when the proportion of infections
leading to chronic carriage was 90% lower, resulting in a
comparable reduction in the prevalence of chronic carriers (Figure
S5).
The model predicted that vaccination should provide little or no
indirect protection if carriers were primarily responsible for driving
transmission (cp=95%) (Figure 2). While this was consistent with
the levels of overall and indirect protection observed during the
cluster randomized trial conducted in Karachi [17], it was not
consistent with the results from Kolkata [16]. As r decreased, the
predicted level of indirect and overall protection increased
substantially. The overall effectiveness observed in Kolkata was
most consistent with values of cp between 25% and 75%
(corresponding roughly to r between 0.01 and 0.1). Therefore, r
was constrained to be between 0.01 and 1 when fitting the model
to the Vellore data. The best-fit model consistently estimated r to
Figure 2. Relationship between the relative infectiousness of chronic carriers and the model-predicted overall and indirect effects
of vaccination. (A) Overall effect and (B) indirect effect of ViPS over two years following vaccine introduction at coverage levels varying from 0 to
100%. The model-predicted vaccine effects over 2 years of follow-up for cp=5 to 95% are represented by the thick coloured lines, while the
population direct effect is represented by the dotted black line. Mass vaccination consisted of a one-time campaign among all individuals $2 years of
age, while school-based vaccination consisted of a one-time campaign among 2–15 year olds. The overall and indirect effects observed during cluster
randomized trials conducted in Kolkata, India and Karachi, Pakistan are plotted in yellow, with the thin black line corresponding to the 95%
confidence interval [16,17].
doi:10.1371/journal.pntd.0002642.g002
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carriers play a limited role in transmission in this setting.
Overall effectiveness and impact of vaccination
Following a one-time vaccine campaign among 6–15 year-old
children, the incidence of typhoid in Vellore is predicted to
decrease substantially within the first year and remain low for a
period of 5–10 years (Figure 3A). The expected reduction in
incidence depends on the vaccine efficacy (i.e. is greater for ViCV
than for Ty21a), but exceeds that due to the direct protection
alone for all three vaccines. However, the incidence of typhoid is
projected to rebound to a level similar to or slightly above the
average pre-vaccination incidence 7–17 years after vaccine
introduction. The rebound occurs slightly sooner if vaccine-
induced immunity wanes after 3 years (ViPS). However, the
rebound in incidence is projected to occur even when there is no
waning of clinical immunity, as we assume for Ty21a.
Routine vaccination of 6 year olds is predicted to lead to a less
substantial reduction in typhoid incidence during the first year
following introduction, but the decline is more sustained
(Figure 3B). Typhoid incidence is predicted to decline by 26%
over 20 years following introduction of Ty21a, and by 36–42%
over 20 years following introduction of ViCV depending on the
age at vaccination. ViPS is predicted to lead to the smallest long-
term decline in incidence (11% decline over 20 years).
Routine vaccination along with a one-time catch-up campaign
is predicted to lead to the largest decline in incidence (Figure 3C).
However, when vaccine-induced immunity wanes, the incidence is
again expected to rebound slightly after 10 or more years,
particularly for ViPS, despite continued routine vaccination
(Figure 3C).
The overall effectiveness over the first 10 years following vaccine
introduction is expected to exceed the population direct effect for
all coverage levels (Figure 4). Thus, vaccination is predicted to
Figure 3. Predicted impact of vaccination on the weekly incidence of typhoid. Vaccination is introduced in year 5 with 80% coverage as (A)
a one-time campaign among 6–15 year olds, (B) routine vaccination of 6 year olds, or (C) routine vaccination of 6 year olds plus a one-time catch-up
campaign among 6–15 year olds. The red line represents the model-predicted overall effect of vaccination, while the green line represents the
population direct effect of vaccination and the dotted blue line is the projected typhoid incidence in the absence of vaccination.
doi:10.1371/journal.pntd.0002642.g003
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levels exceeding 40–50%. Administering ViCV at 9 months of age
leads to an increase in the overall effectiveness for all scenarios,
suggesting a considerable benefit could be derived from vaccinat-
ing infants.
The per-course impact of the different vaccination strategies is
generally low (#5 cases averted per 1,000 courses) during the first
year following vaccine introduction, but increased with the
duration of follow-up for most strategies (Table 2). Routine
vaccination with ViCV at 9 months of age generally prevented the
most cases per course compared to all other vaccination strategies.
Additional vaccination scenarios
Revaccinating school-aged children every 3 years with ViPS is
predicted to provide a substantial benefit compared to only
vaccinating at 6 years of age, and prevents the incidence of typhoid
from rebounding to pre-vaccination level (Figure 5). The overall
effectiveness of vaccination is greater for all coverage levels when a
Figure 4. Overall effect of vaccination on the projected incidence of typhoid over the first 10 years following vaccine introduction.
The model-predicted reduction in the cumulative incidence of typhoid at coverage levels ranging from 0 to 100% is plotted for vaccine-induced
immunity and efficacy assumptions corresponding to (A) the Ty21a live oral vaccine, (B) the Vi-polysaccharide (ViPS) vaccine, and (C) the Vi-conjugate
(ViCV) vaccine administered at 6 years of age or (D) 9 months of age. The red line represents the model-predicted overall effect of vaccination, while
the green line represents the population direct effect of vaccination. The dotted black line represents the population coverage (i.e. the proportiono f
the population ever vaccinated).
doi:10.1371/journal.pntd.0002642.g004
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but the added benefit is lost 10–20 years following the campaign.
While revaccinating with ViPS every three years initially
prevented fewer cases per dose than only vaccinating once, the
per-dose impact of revaccination was greater over 20 years of
follow-up, since it prevented the incidence of typhoid from
rebounding (Table 2).
An aggressive vaccination scenario consisting of a mass
vaccination campaign using ViCV (targeting all age groups)
followed by routine vaccination of 9 month, 6 year, and 12 year
olds should lead to a .85% reduction in typhoid incidence at 80%
coverage, but it is unlikely that typhoid would be eliminated
(Figure 5). Mass vaccination with ViCV followed by routine
vaccination of infants and school-aged children prevented fewer
cases per dose compared to the other ViCV strategies (Table 2).
Impact of improvements in sanitation
Combining vaccination with on-going improvements in sanita-
tion is expected to lead to a sustained decline in typhoid incidence
under most scenarios, and could potentially lead to elimination
(Figure 6). When improvements in water quality/sanitation are
modeled together with vaccination, most of the model-predicted
decline in incidence comes from the impact of sanitation (Figure 6).
Vaccination helps speed up the decline in incidence when carriers
are less important (cp#25%), and offers some additional benefit over
sanitation alone in the long run when water-borne transmission is
less important (R0,w/R0,50%). Under most assumptions about
relative infectiousness of carriers and proportion of transmission
that is water-borne, there is no appreciable rebound in incidence,
with the exception of when R0,w/R0=25% and carrier are less
important (cp#25%). It may be possible to eliminate typhoid (i.e.
decrease incidence to the point where stochastic fadeout would
likely occur) through improvements in water quality/sanitation
when R0,w/R0$75%, or if R0,w/R0=50% and cp=5%), (Figure 6).
Discussion
The World Health Organization (WHO) currently recommends
immunization of school-aged children against typhoid in endemic
areas, but notes that the delivery strategy and vaccine type should
depend on local considerations [6]. Country-level policymakers
need to evaluate the relative merits of different typhoid vaccines
and vaccination strategies. Mathematical modeling allows for a
quantification of the expected long-term impact of different
typhoid vaccination strategies, taking into account both the direct
and indirect effects, and hence can be a helpful tool for
policymakers.
All the typhoid vaccines we modeled were predicted to provide
considerableshort-termindirectprotection.However,undercertain
scenarios, the incidence of typhoid is expected to rebound after a
period of 5–15 years. This is in line with intuition given the build-up
of susceptible individuals following a one-off campaign, since the
indirect protection only serves to delay the time to infection of
unvaccinated individuals. When vaccine-induced immunity wanes
over time, it is possible that the incidence of typhoid during this
rebound period could exceed the pre-vaccination incidence,
although this has yet to be observed for typhoid. However, even
successful routine vaccination with a fully immunizing vaccine (at a
level below that necessary for elimination) can produce a
‘‘honeymoon period’’ after which cases rebound following the
build-up of susceptibles, leading to a ‘‘post-honeymoon outbreak’’,
as has been observed for measles [26].
Following the introduction of school-based vaccination in
Thailand in 1977, the incidence of typhoid declined by 43% in
Table 2. Cumulative number of typhoid cases prevented per 1,000 vaccine courses when vaccination is introduced with 80%
coverage.
Vaccination scenario Number of years post-introduction
Vaccine Age at routine vaccination
Age range of
campaign 1 year 5 years 10 years 20 years
One-time campaign
Ty21a 6–15 y 3.2 15.5 24.9 32.1
ViPS 6–15 y 4.6 14.2 13.0 8.9
ViCV 6–15 y 5.3 23.8 35.2 33.8
ViCV 9 m–15 y 4.6 21.4 34.5 35.7
Routine vaccination
Ty21a 6 y 2.1 11.7 19.0 27.6
ViPS 6 y 3.7 12.1 13.8 11.2
ViPS 6, 9, 12 y 2.7 8.8 11.1 13.7
ViCV 6 y 4.2 19.9 29.8 38.1
ViCV 9 m 5.0 22.6 33.2 41.9
Routine vaccination + catch-up campaign
Ty21a 6 y 6–15 y 3.0 12.9 20.1 28.2
ViPS 6 y 6–15 y 4.3 12.5 13.3 10.6
ViPS 6, 9, 12 y 6–15 y 3.7 9.2 11.4 14.1
ViCV 6 y 6–15 y 4.9 19.3 28.6 36.5
ViCV 9 m 9 m–15 y 4.4 17.9 27.8 37.0
ViCV 9 m, 6 y, 12 y 9 m–15 y 5.1 15.2 20.0 23.7
doi:10.1371/journal.pntd.0002642.t002
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was observed, despite the discontinuation of the vaccination
program in the early 1990s [8]. A number of factors may help
explain why typhoid incidence has remained low. First, the
duration of protection from the whole cell vaccine used in
Thailand may be longer than for ViPS [27]. Second, the 7–12
year old population was targeted for vaccination each year,
resulting in annual revaccination of school children [7]. Third, the
vaccination campaign occurred following a widespread epidemic,
which may have led to high levels of natural immunity in the
population [7,8]. Finally, on-going improvements in water quality,
sanitation, and living conditions likely also played a role [8]. If we
allow for a reduction in long-cycle transmission from current levels
to zero over a 30-year period, our model predicts little to no
rebound in incidence under most circumstances (Figure 6).
Our analysis suggests improvements in sanitation can have a
more lasting impact than vaccination and eventually lead to the
elimination of typhoid. However, in order to determine the
specific benefit of improved water quality and sanitation in
Vellore, we would need better estimates of the relative role of long-
cycle (water-borne) versus short-cycle transmission and chronic
carriers in this setting. While the best-fit model tended to
emphasize short-cycle over long-cycle transmission in Vellore,
the estimates of R0,w and R0,p were highly correlated (Figure S4).
Furthermore, we did not account for improvements in water
quality that may have been occurring in Vellore when fitting our
model to the data. Epidemiological studies from Kathmandu,
Nepal suggest that water-borne transmission may be the dominant
modality in other settings [28]. A better understanding of how
markers of improved water quality correlate with decreased
transmission of typhoid is needed. History suggests that the
introduction of filtration and chlorination of the water supply can
lead to the eventual elimination of typhoid. An analysis of
historical typhoid data from countries that successfully eliminated
typhoid may help in this endeavor.
Previous attempts to model the impact of vaccination on the
transmission dynamics of typhoid have been made, but these
models did not take into account the characteristics of the current
and next generation vaccines nor attempt to differentiate between
the direct and indirect effects of vaccination [18–20]. Our results
are qualitatively similar to those of Cvjetanovic et al. [18], yet their
model considered mass vaccination using whole cell vaccines,
which are no longer available. More broadly, this is to our
knowledge the first parsimonious typhoid model explicitly fitted to
Figure 5. Impact and effectiveness of revaccination with Vi-based vaccines. Revaccination strategies include routine vaccination with ViPS
at 6, 9, and 12 years of age; routine vaccination with ViPS of 6, 9, and 12 year olds plus a one-time catch-up campaign among 6–15 year olds; and
routine vaccination with ViCV at 9 months, 6 years, and 12 years of age with a one-time mass vaccination campaign. (A) Impact of vaccination on the
projected weekly incidence of typhoid. Vaccination is introduced in year 5 with 80% coverage. The red line represents the model-predicted overall
effect of vaccination, while the green line represents the direct effect of vaccination and the dotted blue line is the projected typhoid incidence in the
absence of vaccination. (B) The model-predicted reduction in the cumulative incidence of typhoid due to the overall (red line) and population direct
(green line) effects of vaccination at coverage levels ranging from 0 to 100%, and the population coverage (black dotted line).
doi:10.1371/journal.pntd.0002642.g005
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examine the potential impact of vaccination.
Most ifnotalloftheparametersweestimated byfittingourmodel
to the data on typhoid patients from CMC hospital in Vellore are
likely to be setting-specific. Therefore, our parameter estimates
should not be over-interpreted or extrapolated to other settings. For
example, we found that the age distribution of typhoid cases in
Dhaka, Bangladesh was consistent with a higher basic reproductive
number (R0,7) in this setting [29]. Furthermore, we estimated the
rate of waning immunity to clinical disease (e) to be very low,
consistent with another recent modeling study [21]. However, this
may be due to the relatively high incidence of typhoid infection in
this population leading to continual boosting of immunity through
reinfections. Individuals have been known to experience more than
one episode of clinical typhoid infection [30], so this finding should
be interpreted cautiously. The development of clinical typhoid may
depend on both the immune history of the individual as well as the
infecting dose [31], but our parsimonious model does not explicitly
account for the dose-response relationship. More extensive explo-
rations of how model parameters vary by location and based on
assumptions about model structure are warranted.
We found that assumptions about the relative infectiousness of
chronic carriers, and hence the role they play in transmission, are
critically important to the level of indirect protection expected
from vaccination. Existing typhoid vaccines should have little
impact on the carrier population, since chronic carriers already
exhibit high levels of Vi antibodies [11]. Thus, vaccination only
serves to decrease transmission from short-term clinically and
subclinically infected individuals, and has only a small impact on
carrier prevalence by preventing cases who could go on to become
chronic carriers. If carriers are responsible for driving endemic
typhoid transmission (cp.75%), then vaccination will afford little
indirect protection for unvaccinated individuals.
The levels of indirect protection observed during trials
conducted in Kolkata and other settings suggest that chronic
carriers play a limited role in transmission [10,16]. It is possible
Figure 6. Combined impact of sanitation and vaccination on the projected weekly incidence of typhoid. The model-predicted weekly
number of typhoid cases in Vellore is plotted for values of the proportion of transmission due to chronic carriers (cp) from 5% to 95% and the percent
of transmission that is water-borne (R0,w/R0) from 25% to 100%. Improved sanitation is modeled as a reduction in water-borne transmission (R0,w)
from baseline levels to zero over a 30-year period beginning in year 5. Vaccination is introduced in year 5 with 80% coverage as routine vaccination of
6 year olds plus a one-time catch-up campaign among 6–15 year olds using ViPS vaccines. The red line represents the overall effect of sanitation plus
vaccination, while the light blue line represents the effect of improved sanitation only and the dotted blue line is the projected typhoid incidence in
the absence of any intervention.
doi:10.1371/journal.pntd.0002642.g006
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the discrepant findings from Kolkata and Karachi [16,17].
However, the low levels of overall and indirect protection observed
in Karachi may have been biased by high rates of migration and
diluted as a result of mixing between clusters [17].
We assume 0.3–10.1% of clinically and subclinically infected
individuals become carriers depending on age at infection based
on studies that suggest older individuals (women in particular) are
more likely to become chronic typhoid carriers, possibly due to
underlying gall bladder disease [32–35]. However, most of these
studies are based on the follow-up of convalescent clinical typhoid
cases who did not receive antibiotic treatment [33,34]. It is
possible that treated cases and subclinically infected individuals
may be less likely to become chronic carriers. Furthermore, we
assume that chronic carriage is life-long. Together, these may lead
to overestimation of the prevalence of carriage predicted by our
model (Figure S5, Text S1). If we assume a lower proportion of
cases go on to become chronic carriers, the initial reduction in
typhoid incidence following vaccine introduction was predicted to
be bigger, but this was followed by a larger rebound in incidence
(Figure S6). Thus, the overall effect of vaccination over longer time
scales was similar (Figure S7). Similar results were obtained if we
assumed the relative infectiousness of carriers is lower. There is a
trade-off between the estimated relative infectiousness of carriers
and the average duration of carriage, which is reflected in the
equation for the proportion of transmission due to carriers (cp).
Thus, our estimate for the prevalence and relative infectiousness of
carriers (r) should not be over interpreted, but we believe the
general conclusions are robust.
We advocate that elucidating the precise role of chronic carriers
in transmission, and how it varies between settings, is a crucial
research priority for understanding how to tackle local and
regional elimination. Examining the genotypes of infecting typhoid
bacteria may help shed light on the role of carriers in driving
endemic transmission, since chronic carriers will tend to shed
more ancestral strains [5]. Vaccine probe studies using a cluster-
randomized design could also be used to correlate the role of
chronic carriers with observed levels of indirect protection.
Country-level policymakers and international advisory boards
will have to decide the best way to utilize existing typhoid vaccines
and the soon-to-be-licensed ViCV. Mathematical modeling
provides a powerful tool to test and compare different vaccination
strategies, but the models must be rigorously fit to data and
validated against early observations for the impact of vaccination.
Our analysis suggests that both current and next-generation
typhoid vaccines are likely provide substantial direct and indirect
protection, but it is unlikely typhoid can be eliminated from a mid-
to high-incidence setting such as Vellore through vaccination
alone. Therefore, vaccination should be considered in conjunction
with a suite of interventions, including improved treatment
strategies, better detection and treatment of chronic carriers, and
improvements in water and sanitation. We have provided a
platform for understanding typhoid transmission dynamics that
can be extended to other settings and used to assess additional
control strategies.
Supporting Information
Figure S1 Diagram of typhoid model structure includ-
ing vaccination. (A) Model structure without vaccination (black
lines) and vaccination with live-oral Ty21a (red lines), which is
assumed to mimic natural immunity. (B) Vaccine-induced
immunity for Vi-based vaccines (ViPS and ViCV) is assumed to
be distinct from natural immunity and ‘‘all-or-nothing’’. The
compartments, arrows, and rates describing vaccination are in red.
All other rates are as described in (A).
(TIF)
Figure S2 Comparison between model-predicted vac-
cine efficacy and observed vaccine efficacy for Vi-
polysaccharide vaccines and Vi-conjugate vaccines. The
red line represents the model-predicted direct effect of vaccination
when coverage is low (10%) during year 1–5 of follow-up, while
the black circles and lines represent the summarized observed
vaccine efficacy and 95% confidence interval [9] for (A) Vi-
polysaccharide (ViPS) vaccines and (B) Vi-conjugate (ViCV)
vaccines.
(EPS)
Figure S3 Weekly incidence and age distribution of
typhoid and paratyphoid inpatients at Christian Medi-
cal College hospital in Vellore, India. (A) Number of
patients discharged with a diagnosis of typhoid (blue) or
paratyphoid (green) per week between January 2000 and February
2012. (B) Average number of typhoid and paratyphoid cases per
week of the year (blue and green lines, respectively) along with
average monthly rainfall in Vellore (black line, in millimetres). (C)
Proportion of typhoid and paratyphoid cases by age (in 5-year age
groups).
(EPS)
Figure S4 Likelihood profiles for estimated model
parameters. The negative log-likelihood is plotted in blue for
parameter values around the estimated value for the best-fit model
(blue asterisk) and within the constrained parameter ranges. The
black dotted line represents the cut-off value for the 95%
confidence intervals, corresponding to a chi-squared distribution
with 1 degree of freedom. The negative log-likelihood when
varying R0,p and R0,w together (holding qR0,w constant) is also
plotted.
(EPS)
Figure S5 Prevalence of chronic carriers by age pre-
dicted by the model. Mean proportion of the population in age
class a predicted to be in the C state for (A) the baseline model
fitted to the typhoid data from Vellore, India, and (B) the model
assuming the proportion of infections leading to chronic carriage
was reduced by 90% (i.e. h=0.0003–0.0101 depending on age).
(EPS)
Figure S6 Predicted impact of vaccination assuming the
probability of becoming a chronic carrier following
infection is reduced by 90%. Vaccination is introduced in
year 5 with 80% coverage as (A) a one-time campaign among 6–15
year olds, (B) routine vaccination of 6 year olds, or (C) routine
vaccination of 6 year olds plus a one-time catch-up campaign
among 6–15 year olds. The red line represents the model-
predicted overall effect of vaccination, while the green line
represents the population direct effect of vaccination and the
dotted blue line is the projected typhoid incidence in the absence
of vaccination.
(EPS)
Figure S7 Overall effect of vaccination on the projected
incidence of typhoid assuming the probability of becom-
ing a chronic carrier following infection is reduced by
90%. The model-predicted reduction in the cumulative incidence
of typhoid over the first 10 years following vaccine introduction at
coverage levels ranging from 0 to 100% is plotted for vaccine-
induced immunity and efficacy assumptions corresponding to (A)
the Ty21a live oral vaccine, (B) the Vi-polysaccharide (ViPS)
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6 years of age or (D) 9 months of age. The red line represents the
model-predicted overall effect of vaccination, while the green line
represents the population direct effect of vaccination. The dotted
black line represents the population coverage (i.e. the proportion
of the population ever vaccinated).
(EPS)
Figure S8 Overall effectiveness of different typhoid
vaccination strategies in a high incidence setting. (A)
Age distribution of typhoid cases in Dhaka, Bangladesh [29] and
predicted by the model with R0=7. We assume the reporting rate
is 50% lower in infants ,1 year of age. (B) Percent reduction in the
cumulative incidence of typhoid due to the overall effect of
vaccination at 80% coverage. The bars show the model-predicted
reduction in typhoid incidence over the first 1 year, 5 years, 10
years, and 20 years following vaccine introduction. The white bars
represent school-based vaccination assumptions corresponding to
the Ty21a live oral vaccine; the light grey bars represent the Vi-
polysaccharide (ViPS) vaccine; the medium grey bars represent
revaccination every three years with ViPS; the dark grey bars
represent Vi-conjugate (ViCV) vaccine administered at 6 years of
age; and the black bars represent the ViCV vaccine administered
at 9 months of age.
(EPS)
Table S1 Sensitivity of estimated parameters to fixed
parameter assumptions.
(PDF)
Table S2 Summary of vaccination parameters.
(PDF)
Text S1 Detailed methods.
(PDF)
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